“Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s31. doi:10.25251/skin.4.supp.31.